A5085875361- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Breast Lesions and Carcinomas
- Global Cancer Incidence and Screening
- HIV/AIDS drug development and treatment
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- DNA Repair Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Histone Deacetylase Inhibitors Research
- Immunotherapy and Immune Responses
- CNS Lymphoma Diagnosis and Treatment
- Cancer Risks and Factors
Icahn School of Medicine at Mount Sinai
2014-2025
Montefiore Medical Center
2015-2024
Tisch Cancer Institute
2021-2024
Tisch Hospital
2022-2024
Mount Sinai Hospital
2022-2024
Mount Sinai Health System
2022-2024
Albert Einstein College of Medicine
2014-2023
Northwestern University
2002-2022
Dana-Farber Cancer Institute
2012-2022
Cornell University
2006-2022
The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of in absence low; however, there uncertainty about for most patients, who have midrange score.We performed prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative cancer. Of 9719 eligible patients follow-up information, 6711 (69%) had 11 to 25 were randomly assigned receive...
Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, prospectively conducted study in uniformly treated population provides highest level evidence supporting clinical validity and usefulness biomarker.We performed prospective trial involving women hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary...
Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs primary TNBCs two adjuvant phase III trials conducted by Eastern Cooperative Oncology Group (ECOG).Full-face hematoxylin eosin–stained sections 506 tumors from ECOG E2197 E1199 were evaluated for density intraepithelial (iTILs) stromal compartments (sTILs). Patient...
We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in adjuvant treatment breast cancer.
Standardized definitions of breast cancer clinical trial end points must be adopted to permit the consistent interpretation and analysis trials facilitate cross-trial comparisons meta-analyses. Standardizing terms will allow for uniformity in data collection across studies, which optimize utility efficiency. A given point term (eg, overall survival) used a should always encompass same set events death attributable cancer, cause other than from unknown cause), and, turn, each event within...
Abstract Patients with cancer are presumed to be at increased risk from COVID-19 infection–related fatality due underlying malignancy, treatment-related immunosuppression, or comorbidities. A total of 218 COVID-19–positive patients March 18, 2020, April 8, a malignant diagnosis were identified. 61 (28%) died case rate (CFR) 37% (20/54) for hematologic malignancies and 25% (41/164) solid malignancies. Six 11 (55%) lung disease. Increased mortality was significantly associated older age,...
BackgroundFor women with ductal carcinoma in situ (DCIS) of the breast, risk developing an ipsilateral breast event (IBE; defined as local recurrence DCIS or invasive carcinoma) after surgical excision without radiation is not well by clinical and pathologic characteristics.
The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on 21-gene assay to determine the risk recurrence. Whether level clinical recurrence adds prognostic information is not known.
Breast cancer cells disseminate through TIE2/MENA
This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality life (QOL), fatigue, distressed mood, spiritual well-being among a multiethnic sample breast cancer patients.One hundred twenty-eight patients (42% African American, 31% Hispanic) recruited from an urban center were randomly assigned (2:1 ratio) to 12-week yoga intervention (n = 84) or waitlist control group 44). Changes in QOL (eg, Functional Assessment Cancer Therapy) before...
Adjuvant! is a standardized validated decision aid that projects outcomes in operable breast cancer based on classical clinicopathologic features and therapy. Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than features.A sample of 465 patients with hormone receptor (HR) -positive zero three positive axillary nodes did (n = 99) or not have recurrence after chemohormonal therapy had tumor tissue evaluated using 21-gene assay....
The incidence of anal cancer is substantially higher among persons living with the human immunodeficiency virus (HIV) than in general population. Similar to cervical cancer, preceded by high-grade squamous intraepithelial lesions (HSILs). Treatment for HSIL reduces progression cancer; however, data from prospective studies treatment prevent are lacking.
There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at time of this narrative review. The objective review describe current status highlighting its potential both early-stage and metastatic disease.After searching ClinicalTrials.gov on April 24, 2018, PubMed up June 30, identify cancer trials, we found that immune checkpoint blockade (ICB) most investigated form cancer. Use ICB monotherapy has achieved...
To determine the 12-year risk of developing an ipsilateral breast event (IBE) for women with ductal carcinoma in situ (DCIS) treated surgical excision (lumpectomy) without radiation.A prospective clinical trial was performed DCIS who were selected low-risk and pathologic characteristics. Patients enrolled onto one two study cohorts (not randomly assigned): cohort 1: low- or intermediate-grade DCIS, tumor size 2.5 cm smaller (n = 561); 2: high-grade 1 104). Protocol specifications included a...